Author

J. Boisvert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Amzallag· 1 shared A. D. Sahu· 1 shared A. Dastur· 1 shared A. Friedman· 1 shared A. K. Dube· 1 shared A. Pageau· 1 shared A. Tam· 1 shared C. Bedard· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Amzallag

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Most azole antifungal resistance mutations in the drug target provide cross-resistance and carry no intrinsic fitness cost

C. Bedard, I. Gagnon-Arsenault, J. Boisvert, S. Plante, A. K. Dube, A. Pageau, J. Sharma, L. Maroc, R. S. Shapiro, C. R. Landry

The paper evaluates 4,000 Erg11 variants to determine azole resistance and fitness costs, finding 33% resistance, 88% cross-resistance, and minimal fitness cost.

bioRxiv · Dec 13, 2023 · PreprintMicrobiology

A landscape of synergistic drug combinations in non-small-cell lung cancer

N. U. Nair, P. Greninger, A. Friedman, A. Amzallag, E. Cortez, A. D. Sahu, J. S. Lee, A. Dastur, R. K. Egan, E. Murchie, G. S. Crowther, J. McClanaghan, J. Boisvert, L. Damon, J. Ho, , C. H. Benes

The paper identifies synergistic drug combinations in non-small-cell lung cancer cell lines, finding that synergy often arises from sensitizing resistant models through dual pathway targeting.

bioRxiv · Jun 3, 2021 · PreprintCancer Biology